Breast CancerNCT05142787
Magseed Pro(R)/ Sentimag(R) Gen3
A study testing Magseed Pro(R) and Sentimag(R) Gen3 by Endomagnetics in people with Breast Cancer, run by Endomagnetics Ltd. at 6 sites in 2 countries.
Trial summary
The purpose of this study is to provide prospective evidence that the Magseed Pro® marker /Sentimag® Gen3 system is safe and effective for marking A. suspicious/biopsy-proven positive axillary lymph nodes; and B. soft tissue lesions including cancer and pre-cancerous change in the breast Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Breast Cancer
- What is being tested?
- Magseed Pro(R) and Sentimag(R) Gen3 by Endomagnetics
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 224 participants
- Where
- 6 sitesin 2 countries
- Study dates
- 2 Mar 2023to 30 Jun 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Participant is willing and able to give informed consent for participation in the study
- Participant is aged 18 years or older at the time of consent.
- Patients requiring breast lesion/axillary node marking and excision
- Exclusion Criteria:• Pregnant or nursing subjects and those who plan pregnancy during the clinical investigation follow-up period. A pregnancy test is required for all women of childbearing potential within 7 days before enrolment.
- Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical trial or to comply with follow up requirements, or impact the scientific soundness of the clinical trial results
- Known hypersensitivity to Nitinol
- Subject has current active infection at the implantation site in the breast (per investigator discretion)
Who cannot join
None listed.
Trial locations and contacts
6 sites in 2 countries. Contact the study team or a site near you to ask about taking part.
6 sites in 2 countries
Germany3 sites, 3 recruiting
- Recruiting
Marienhospital Bottrop GmbH
Bottrop
Hans Christian Kolberg
- Recruiting
AGAPLESION Markus Frankfurter Diakonie Kliniken gGmbH
Frankfurt
Marc Thill
- Not yet recruiting
Technical University Munich
Munich
Stefan Paepke
United Kingdom3 sites, 3 recruiting
- Recruiting
Guy's Hospital
London
Ashutosh Kothari
- Recruiting
Royal Marsden Hospital
London
Peter Barry
- Recruiting
University Hospital South Manchester
Manchester
James Harvey
About this study
Official title: A Prospective, Multi Center, International, Open Label Study of the Use of Magseed Pro(R) Markers and Sentimag(R) Gen3 to Localize Breast Lesions and Suspicious/Biopsy-proven Positive Lymph Nodes in Breast Cancer Patients
The purpose of this study is to provide prospective evidence that the Magseed Pro® marker /Sentimag® Gen3 system is safe and effective for marking A. suspicious/biopsy-proven positive axillary lymph nodes; and B. soft tissue lesions including cancer and pre-cancerous change in the breast
Read the detailed description
The purpose of this study is to provide prospective evidence that the Magseed Pro® marker /Sentimag® Gen3 system is safe and effective for marking A. suspicious/biopsy-proven positive axillary lymph nodes; and B. soft tissue lesions including cancer and pre-cancerous change in the breast The devices used in this clinical trial are the Magseed Pro® marker and Sentimag® Gen3 system by Endomagnetics Limited.
The Endomag Magseed Pro® Marker System is intended to be placed within the target soft tissue prior to planned surgical removal. The marker, when used in conjunction with the Sentimag® Gen 3 System, can be used as a guide for the surgeon to follow in the excision of tissue. The Sentimag® Gen3 Magnetic Localisation System when used with the Magseed family of markers is indicated to assist in localising soft tissue lesions.
The study design is a multicentre international prospective, open label, study of Magseed Pro® marker and Sentimag® Gen3 system in patients with breast and/or lymph node pathology with:
- axillary lymph nodes requiring localisation prior to surgical excision (suspicious and/or biopsy proven lymph node or other pathology indicating removal) and/or B. breast lesions requiring localisation
Patients will have the Magseed Pro® marker placed to mark A. surgical excision of suspicious/biopsy-proven axillary lymph node as part of a targeted lymph node biopsy procedure AND/OR B. breast lesions in patients undergoing surgical excision of the targeted breast lesion The Magseed Pro® marker will be localised using the Sentimag® Gen3 system and therafter surgically removed with the target tissue.
This study will enrol 224 patients; 112 with Magseed Pro® marker placed to mark breast lesions and 112 with Magseed Pro® marker placed to mark nodes.
The expected duration of enrolment is approximately 9 months across all sites with each individual subject's participation lasting approximately 1-38 weeks after enrolment.
- Conditions
- Breast Cancer
- Being tested
- Magseed Pro(R) and Sentimag(R) Gen3 by Endomagnetics
- Keywords
- Magseed Pro, Sentimag Gen3
- Medical subject headings
- Breast Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Magseed Pro(R) and Sentimag(R) Gen3 by EndomagneticsDevice
placement of Magseed Pro \& localisation with Sentimag Gen3 in axillary lymph nodes and/or breast lesions
| Study group | Role | What they receive |
|---|---|---|
| axillary lymph nodes requiring localisation prior to surgical excision | Other | The Magseed Pro® marker is intended to be placed percutaneously in suspicious/biopsy proven positive axillary lymph nodes under imaging guidance to mark tissue intended for selective surgical removal.
The Magseed Pro® marker is localised using the Sentimag® Gen3 system handheld probes and surgically removed within/from the target tissue. Receives: Device: Magseed Pro(R) and Sentimag(R) Gen3 by Endomagnetics |
| breast lesions requiring localisation | Other | The Magseed Pro® marker is intended to be placed percutaneously in breast lesions under imaging guidance to mark tissue intended for selective surgical removal.
The Magseed Pro® marker is localised using the Sentimag® Gen3 system handheld probes and surgically removed within/from the target tissue. Receives: Device: Magseed Pro(R) and Sentimag(R) Gen3 by Endomagnetics |
What is being measured
The primary outcome is the main question the study is designed to answer.
The primary endpoints are the retrieval rates of the Magseed Pro® marker with the target lesion within the initial excised specimen for A.) axillary lymph nodes B.) breast lesions A.) axillary lymph nodes. B.) breast lesions
This is defined as the number of patients with successful Magseed Pro® marker placement as demonstrated on imaging, in whom the Magseed Pro® marker and the associated lymph node and/ or lesion is retrieved, divided by the total number of subjects.
Measured: time of surgery
Secondary outcomes (27)
Tissue response (unexpected and expected)
EXPECTED Early (up to 2 days) - acute inflammation in the form of neutrophils with lymphocytes and some associated haemorrhage.
Late (>2 days) - active chronic inflammation in the form of neutrophils, lymphocytes, macrophages together with a fibroblastic response. Likely a foreign body reaction with increased numbers of histiocytes and some multinucleated giant cells. Possible granuloma formation (foreign body type). Scattered eosinophils. Later scarring (after 1-2 weeks) with fibrosis. Possible fat necrosis.
UNEXPECTED Early and Late -
- Very florid fibroblastic response with granulation tissue formation that mimics malignancy (nodular fasciitis-like), which may need immunohistochemical tests to differentiate between reactive chan
Measured: time of surgery
Presence of unexpected histological tissue response for short- and long-term use of Magseed Pro marker
UNEXPECTED HISTOLOGICAL RESPONSE Early and Late -
- Very florid fibroblastic response with granulation tissue formation that mimics malignancy (nodular fasciitis-like), which may need immunohistochemical tests to differentiate between reactive chan
Measured: time of surgery
Rate of device-related AE's and SAE's
Rate of device-related AE's and SAE's
Measured: through study completion, an average of 38 weeks
Retrieval rate for all lesions
Retrieval rate for all lesions (including target, non-target lesions and multiple lesions per patient) out of the total number of lesions with a Magseed Pro® marker placement. Non-target lesions include additional marked lesions which weren't defined as the target for the primary endpoint and any marked lesions from patients undergoing long term node retrieval.
Measured: time of surgery
Retrieval rate for all nodes
Retrieval rate for all nodes (including multiple nodes per patient where applicable) out of the total number of nodes with a Magseed Pro® marker placement.
Measured: time of surgery
Per lesion retrieval rate for target excised specimens
Per lesion retrieval rate for target excised specimens
Measured: time of surgery
Per lesion retrieval rate for all excised specimens
Per lesion retrieval rate for all excised specimens
Measured: time of surgery
Per lesion retrieval rate for all lesion
Per lesion retrieval rate for all lesion
Measured: time of surgery
Per lesion retrieval rate for all nodes
Per lesion retrieval rate for all nodes
Measured: time of surgery
Per patient retrieval rate for Magseed Pro® marker placed prior to neo-adjuvant therapy and retrieved post neo-adjuvant therapy
Per patient retrieval rate for Magseed Pro® marker placed prior to neo-adjuvant therapy and retrieved post neo-adjuvant therapy
Measured: time of surgery
Per lesion retrieval rate for Magseed Pro® marker placed prior to neo-adjuvant therapy and retrieved post neo-adjuvant therapy.
Per lesion retrieval rate for Magseed Pro® marker placed prior to neo-adjuvant therapy and retrieved post neo-adjuvant therapy.
Measured: time of surgery
Per patient retrieval rate for Magseed Pro® marker where retrieval surgery is within 30 days of placement.
Per patient retrieval rate for Magseed Pro® marker where retrieval surgery is within 30 days of placement.
Measured: time of surgery
Per lesion retrieval rate for Magseed Pro® marker where retrieval surgery is within 30 days of placement.
Per lesion retrieval rate for Magseed Pro® marker where retrieval surgery is within 30 days of placement.
Measured: time of surgery
Per patient retrieval rate for Magseed Pro® marker where retrieval surgery is greater than 30 days after placement
Per patient retrieval rate for Magseed Pro® marker where retrieval surgery is greater than 30 days after placement
Measured: time of surgery
Per lesion retrieval rate for Magseed Pro® marker where retrieval surgery is greater than 30 days after placement.
Per lesion retrieval rate for Magseed Pro® marker where retrieval surgery is greater than 30 days after placement.
Measured: time of surgery
Per lesion retrieval rate for target excised specimens (i.e., lesions plus nodes) where Magtrace® Tracer is present in the target node or in the region of the target lesion.
Per lesion retrieval rate for target excised specimens (i.e., lesions plus nodes) where Magtrace® Tracer is present in the target node or in the region of the target lesion.
Measured: time of surgery
Per lesion retrieval rate for all excised specimens (i.e., lesions plus nodes) where Magtrace® Tracer is present in the target node or in the region of the target lesion.
Per lesion retrieval rate for all excised specimens (i.e., lesions plus nodes) where Magtrace® Tracer is present in the target node or in the region of the target lesion.
Measured: time of surgery
Per lesion retrieval rate for target lesions where Magtrace® Tracer is present in the region of the target lesion.
Per lesion retrieval rate for target lesions where Magtrace® Tracer is present in the region of the target lesion.
Measured: time of surgery
Per lesion retrieval rate for all lesions where Magtrace® Tracer is present in the region of the lesion.
Per lesion retrieval rate for all lesions where Magtrace® Tracer is present in the region of the lesion.
Measured: time of surgery
Per node retrieval rate for target nodes where Magtrace® Tracer is present in the target node.
Per node retrieval rate for target nodes where Magtrace® Tracer is present in the target node.
Measured: time of surgery
Per node retrieval rate for all nodes where Magtrace® Tracer is present in the node.
er node retrieval rate for all nodes where Magtrace® Tracer is present in the node.
Measured: time of surgery
Interventionist rated ease of Magseed Pro® marker placement by the interventionist
5 point Likert scale, very easy = 5, very difficult = 1
Measured: seed placement
Rate of deployment failure
A Magseed Pro is not deployed from the needle, or is accidentally deployed prior to use in the patient
- Success rate of seed placement:
- Accurate: Within the breast lesion or clipped lymph node. For lesions less than 5 mm in size the marker may not necessarily be within the excised specimen but should be within 10mm1 of the lesion.
- Inadequate: Not in the targeted lesion or clipped lymph node determined by placement imaging requiring additional marker placement
Measured: seed placement
Surgeon rated ease of intra-operative localisation
5 point Likert scalevery easy = 5, very difficult = 1
Measured: time of surgery
Magtrace® Tracer counts for excised lymph nodes during SLNB procedures
Magtrace® Tracer counts for excised lymph nodes during SLNB procedures
Measured: time of surgery
Re-excision rate (i.e., second procedure required). With reason for second procedure.
Re-excision rate (i.e., second procedure required). With reason for second procedure.
Measured: time of surgery
Success rate of maintained marker position at the time of removal as determined by specimen X-ray and or Sentimag Gen3 system.
- Accurate: Magseed Pro® marker within the target lesion or marked lymph node.
- Inadequate: Magseed Pro® marker not within the target lesion or marked lymph node
Measured: time of surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Dec 2021
- Study start2 Mar 2023
- Primary completion31 Dec 2027 (estimated)
- Study completion30 Jun 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Breast CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 224 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Endomagnetics Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Stefan Paepke, Dr, Principal investigator, The technical university of Munich
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05142787
- Sponsor's protocol ID
- EU001
- Status last verified
- Sep 2026
- First submitted
- 8 Nov 2021
- Last updated
- 16 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective, Multi Center, International, Open Label Study of the Use of Magseed Pro(R) Markers and Sentimag(R) Gen3 to Localize Breast Lesions and Suspicious/Biopsy-proven Positive Lymph Nodes in Breast Cancer Patients
- ClinicalTrials.gov ID
- NCT05142787
- Acronym / sponsor ID
- EU001
- Conditions
- Breast Cancer
- Keywords
- Magseed Pro, Sentimag Gen3
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 224 participants (estimated)
- Lead sponsor
- Endomagnetics Ltd.Industry (pharma, biotech, devices)
- Study start
- 2 Mar 2023 (actual)
- Primary completion
- 31 Dec 2027 (estimated)
- Study completion
- 30 Jun 2028 (estimated)
- First posted
- 3 Dec 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to provide prospective evidence that the Magseed Pro® marker /Sentimag® Gen3 system is safe and effective for marking A. suspicious/biopsy-proven positive axillary lymph nodes; and B. soft tissue lesions including cancer and pre-cancerous change in the breast
Detailed description
The purpose of this study is to provide prospective evidence that the Magseed Pro® marker /Sentimag® Gen3 system is safe and effective for marking A. suspicious/biopsy-proven positive axillary lymph nodes; and B. soft tissue lesions including cancer and pre-cancerous change in the breast The devices used in this clinical trial are the Magseed Pro® marker and Sentimag® Gen3 system by Endomagnetics Limited.
The Endomag Magseed Pro® Marker System is intended to be placed within the target soft tissue prior to planned surgical removal. The marker, when used in conjunction with the Sentimag® Gen 3 System, can be used as a guide for the surgeon to follow in the excision of tissue. The Sentimag® Gen3 Magnetic Localisation System when used with the Magseed family of markers is indicated to assist in localising soft tissue lesions.
The study design is a multicentre international prospective, open label, study of Magseed Pro® marker and Sentimag® Gen3 system in patients with breast and/or lymph node pathology with:
- axillary lymph nodes requiring localisation prior to surgical excision (suspicious and/or biopsy proven lymph node or other pathology indicating removal) and/or B. breast lesions requiring localisation
Patients will have the Magseed Pro® marker placed to mark A. surgical excision of suspicious/biopsy-proven axillary lymph node as part of a targeted lymph node biopsy procedure AND/OR B. breast lesions in patients undergoing surgical excision of the targeted breast lesion The Magseed Pro® marker will be localised using the Sentimag® Gen3 system and therafter surgically removed with the target tissue.
This study will enrol 224 patients; 112 with Magseed Pro® marker placed to mark breast lesions and 112 with Magseed Pro® marker placed to mark nodes.
The expected duration of enrolment is approximately 9 months across all sites with each individual subject's participation lasting approximately 1-38 weeks after enrolment.
Study design
- Primary purpose
- Other
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| axillary lymph nodes requiring localisation prior to surgical excision | Other | Device: Magseed Pro(R) and Sentimag(R) Gen3 by EndomagneticsThe Magseed Pro® marker is intended to be placed percutaneously in suspicious/biopsy proven positive axillary lymph nodes under imaging guidance to mark tissue intended for selective surgical removal. The Magseed Pro® marker is localised using the Sentimag® Gen3 system handheld probes and surgically removed within/from the target tissue. |
| breast lesions requiring localisation | Other | Device: Magseed Pro(R) and Sentimag(R) Gen3 by EndomagneticsThe Magseed Pro® marker is intended to be placed percutaneously in breast lesions under imaging guidance to mark tissue intended for selective surgical removal. The Magseed Pro® marker is localised using the Sentimag® Gen3 system handheld probes and surgically removed within/from the target tissue. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Participant is willing and able to give informed consent for participation in the study
- Participant is aged 18 years or older at the time of consent.
- Patients requiring breast lesion/axillary node marking and excision
- Exclusion Criteria:• Pregnant or nursing subjects and those who plan pregnancy during the clinical investigation follow-up period. A pregnancy test is required for all women of childbearing potential within 7 days before enrolment.
- Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical trial or to comply with follow up requirements, or impact the scientific soundness of the clinical trial results
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Magseed Pro(R) and Sentimag(R) Gen3 by Endomagneticsplacement of Magseed Pro \& localisation with Sentimag Gen3 in axillary lymph nodes and/or breast lesions | Device | axillary lymph nodes requiring localisation prior to surgical excision, breast lesions requiring localisation |
Primary outcome
The primary endpoints are the retrieval rates of the Magseed Pro® marker with the target lesion within the initial excised specimen for A.) axillary lymph nodes B.) breast lesions A.) axillary lymph nodes. B.) breast lesions
Time frame: time of surgery
This is defined as the number of patients with successful Magseed Pro® marker placement as demonstrated on imaging, in whom the Magseed Pro® marker and the associated lymph node and/ or lesion is retrieved, divided by the total number of subjects.
27 secondary outcomes
Tissue response (unexpected and expected)
Time frame: time of surgery
Presence of unexpected histological tissue response for short- and long-term use of Magseed Pro marker
Time frame: time of surgery
Rate of device-related AE's and SAE's
Time frame: through study completion, an average of 38 weeks
Retrieval rate for all lesions
Time frame: time of surgery
Retrieval rate for all nodes
Time frame: time of surgery
Per lesion retrieval rate for target excised specimens
Time frame: time of surgery
Per lesion retrieval rate for all excised specimens
Time frame: time of surgery
Per lesion retrieval rate for all lesion
Time frame: time of surgery
Per lesion retrieval rate for all nodes
Time frame: time of surgery
Per patient retrieval rate for Magseed Pro® marker placed prior to neo-adjuvant therapy and retrieved post neo-adjuvant therapy
Time frame: time of surgery
Per lesion retrieval rate for Magseed Pro® marker placed prior to neo-adjuvant therapy and retrieved post neo-adjuvant therapy.
Time frame: time of surgery
Per patient retrieval rate for Magseed Pro® marker where retrieval surgery is within 30 days of placement.
Time frame: time of surgery
Per lesion retrieval rate for Magseed Pro® marker where retrieval surgery is within 30 days of placement.
Time frame: time of surgery
Per patient retrieval rate for Magseed Pro® marker where retrieval surgery is greater than 30 days after placement
Time frame: time of surgery
Per lesion retrieval rate for Magseed Pro® marker where retrieval surgery is greater than 30 days after placement.
Time frame: time of surgery
Per lesion retrieval rate for target excised specimens (i.e., lesions plus nodes) where Magtrace® Tracer is present in the target node or in the region of the target lesion.
Time frame: time of surgery
Per lesion retrieval rate for all excised specimens (i.e., lesions plus nodes) where Magtrace® Tracer is present in the target node or in the region of the target lesion.
Time frame: time of surgery
Per lesion retrieval rate for target lesions where Magtrace® Tracer is present in the region of the target lesion.
Time frame: time of surgery
Per lesion retrieval rate for all lesions where Magtrace® Tracer is present in the region of the lesion.
Time frame: time of surgery
Per node retrieval rate for target nodes where Magtrace® Tracer is present in the target node.
Time frame: time of surgery
Per node retrieval rate for all nodes where Magtrace® Tracer is present in the node.
Time frame: time of surgery
Interventionist rated ease of Magseed Pro® marker placement by the interventionist
Time frame: seed placement
Rate of deployment failure
Time frame: seed placement
Surgeon rated ease of intra-operative localisation
Time frame: time of surgery
Magtrace® Tracer counts for excised lymph nodes during SLNB procedures
Time frame: time of surgery
Re-excision rate (i.e., second procedure required). With reason for second procedure.
Time frame: time of surgery
Success rate of maintained marker position at the time of removal as determined by specimen X-ray and or Sentimag Gen3 system.
Time frame: time of surgery
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for Breast Cancer
Not yet recruiting
Effect of a Health Belief Model Based Digital Nudge Intervention on Breast Cancer Screening
Breast Cancer Screening, Breast Cancer Awareness
Active, not recruitingPhase 1/2
A Beta-only IL-2 ImmunoTherapY Study
Advanced Solid Tumor, Unresectable Solid Tumor
Not yet recruitingPhase 2
Low-Dose Apatinib Plus Chemotherapy in ADC-Pretreated HER2-Positive and HER2-Low Advanced Breast Cancer
Breast Neoplasms, Advanced Breast Cancer
RecruitingPhase 3
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Breast Neoplasms
Active, not recruitingPhase 2
Phase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastases
Breast Cancer Stage IV
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Stefan Paepke, Dr principal investigator
The technical university of Munich
6 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Magseed Pro(R) and Sentimag(R) Gen3 by Endomagnetics in people with Breast Cancer, run by Endomagnetics Ltd. at 6 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 16 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 6 sites in Germany, United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Matt Womack, Dr (+447851247439, mwomack@endomag.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The primary endpoints are the retrieval rates of the Magseed Pro® marker with the target lesion within the initial excised specimen for A.) axillary lymph nodes B.) breast lesions A.) axillary lymph nodes. B.) breast lesions (time frame: time of surgery). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Sep 2026.